[1]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69-73.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):69-73.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
点击复制

儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第2期
页码:
69-73
栏目:
论著
出版日期:
2013-03-25

文章信息/Info

Title:
The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism
作者:
郑艳;  赵德善;  付松海;  冯菲;  耿会霞;  孙琦婷;  陆克义;  李保军;  李思进
山西医科大学第一医院核医学科, 太原, 030001
Author(s):
ZHENG Yan;  ZHAO De-shan;  FU Song-hai;  FENG Fei;  GENG Hui-xia;  SUN Qi-ting;  LU Ke-yi;  LI Bao-jun;  LI Si-jin
Department of Nuclear Medicine, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
格雷夫斯病; 碘放射性同位素; 放射治疗剂量; 近距离放射疗法; 儿童; 青少年
Keywords:
Graves disease; Iodine radioisotopes; Radiotherapy dosage; Brachytherapy; Child; Adolescent
DOI:
10.3760/cma.j.issn.1673-4114.2013.02.002
摘要:
目的 研究儿童和青少年Graves甲状腺功能亢进症(甲亢)患者接受131Ⅰ治疗的剂量范围。方法 回顾性分析经临床确诊、对抗甲状腺药物耐药或有临床禁忌证并接受131Ⅰ治疗的51例儿童和青少年甲亢患者及150例成年甲亢患者。两组患者均按甲状腺质量不同分为5组:第1组:≤30 g、第2组:31~50 g、第3组:51~70 g、第4组:71~90 g和第5组:>90 g,儿童和青少年组与成年组间的各质量组间资料分布具有可比性。儿童和青少年组与成年组患者每克甲状腺组织所给予的131Ⅰ治疗剂量分别为(2.41±0.71) MBq/g和(3.27±0.97) MBq/g;总剂量分别为(224.36±130.10) MBq和(354.88±308.04) MBq.全部患者均行集中随访,儿童和青少年组131Ⅰ治疗后随访时间为24~83个月(平均32个月),成年组的随访时间为15~62个月(平均23个月),治疗结果分为痊愈、好转、甲减和复发。结果 随访结果发现,在接受131Ⅰ治疗的儿童和青少年组中,痊愈16例、出现永久性甲减22例、好转12例、复发1例;在成年组患者中,痊愈65例、出现永久性甲减56例、好转25例、复发4例;总有效率分别为98%和97.3%,儿童和青少年组与成年组的治疗疗效之间的差异无统计学意义(χ2=0.058,P>0.05).结论 在对抗甲状腺药物耐药或有临床禁忌证的儿童和青少年Graves甲亢患者行131Ⅰ治疗时,建议所给予的131Ⅰ应为成年人相应甲状腺质量所给131Ⅰ总剂量的63%左右或每克剂量的74%左右Ⅰ总剂量的63%左右或每克剂量的74%左右。
Abstract:
Objective To analyze the radioactive 131Ⅰ dose of treatment in pediatric patients with Graves hyperthyroidism.Method Fifty one pediatric patients with hyperthyroidism and 150 adult patients with hyperthyroidism were retrospectively analyzed,who were contraindicated or refractory for medical therapy and treated with 131Ⅰ in this study.All pediatric and adult patients treated with 131Ⅰ were divided into five groups according to the thyroid weight.Group1: ≤30 g,Group2:31~50 g,Group3:51~70 g,Group4:71~90 g and Group5:>90 g.The pediatric patients were comparable to the adult patients in data distribution of the thyroid weight.All pediatric patients who were either contraindicated or refractory to antithyroid drugs treatment and adult patients received radioactive 131Ⅰ treatment with a dose of (2.41±0.71),(3.27±0.97)MBq/g thyroid tissue respectively.The total administrated doses of 131Ⅰ in all pediatric and adult patients were (224.36±130.10) MBq and (354.88 ±308.04) MBq respectively.All the pediatric and adult patients treated with 131Ⅰ were followed-up (median 32 months,range 24 to 83 months; median 23 months,range 15 to 62 months,respectively).The treatment results were divided into euthyroid,hyperthyroidism,late-onset hypothyroidism and relapsed.Results The results by followed-up found that 16 and 65 patients became euthyroid,22 and 56 patients developed late-onset hypothyroidism,12 and 25 patients still had hyperthyroidism,1 and 4 patients relapsed after radioiodine therapy in pediatric group and adult group who were treated with 131Ⅰ,respectively.The total efficiency was 98% and 97.3%,respectively.There were no statistical significance of treatment effect between pediatric and adult patients (χ2=0.058,P>0.05).Conclusion When the radioactive 131Ⅰ dose was administrated in pediatric patients with hyperthyroidism,who were contraindicated or refractory for medical therapy,it is recommended that the ratios of total 131Ⅰ dose administrated and that based on per gram thyroid tissue between pediatric and adult patients were 63% and 74%,respectively.

参考文献/References:

[1] Lee SL.Radioactive iodine therapy. Curr Opin Endocrinol Diabetes Obes,2012,19(5):420-428.
[2] Waldhausen JH.Controversies related to the medical and surgical management of hyperthyroidism in children.Semin Pediatr Surg,1997,6(3):121-127.
[3] Freitaz JE.The role of nuclear medicine in the management of Graves,disease.Q J Nucl Med, 1999,43(4):297-306.
[4] 中华医学会.临床技术操作规范(核医学分册).北京:人民军医出版社,2004:175-177.
[5] 中华医学会内分泌分会《中国甲状腺疾病诊断指南》 编写组.中国甲状腺疾病诊治指南-甲状腺功能亢进症.中华内科杂志,2007,46(10):876-882.
[6] 蒋宁一,匡安仁,谭建,等.131I治疗Graves甲亢专家共识(2010年).中华核医学杂志,2010,30(5):346-351.
[7] Bauer AJ.Approach to the pediatric patient with Graves’ disease:when is definitive therapy warranted?.J Clin Endocrinol Metab,2011,96(3):580-588.
[8] Jukic T,Stanicic J,Petrie V,et al.Radioiodine versus surgery in the treatment of Graves’ hyperthyroidism.Lijec Vjesn,2010,132(11-12):355-360.
[9] Peroni E,Angiolini MR,Vigone MC,et al.Surgical management of pediatric Gravesf disease:an effective definitive treatment.Pedi-atr Surg Int,2012,28(6):609-614.
[10] 赵德善,孔繁振,司宏伟,等.儿童和青少年甲状腺机能亢进症的131I治疗.中华内分泌代谢杂志,2006,22(6):566-568.
[11] MaC,Kuang A,Xie J,et al.Radioiodine treatment for pediatric Graves,disease[DB/OL].Cochrane Database Syst Rev,2008[2012-10-23].http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006294.pub2/pdf.
[12] Rivkees SA.Pediatric Graves’ disease:controversies in manage-ment.Horm Res Paediatr,2010,74(5):305-311.
[13] Flynn RW,Macdonald TM,Jung RT,et al.Mortality and vascular outcomes in patients treated for thyroid dysfunction.J Clin Endocrinol Metab,2006,91(6):2159-2164.
[14] Franklyn JA,Sheppard MC,Maisonneuve P.Thyroid function and mortality in patients treated for hyperthyroidism.JAMA,2005,294(1):71-80.
[15] Read CH Jr,Tansey MJ,Menda Y.A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients.J Clin Endocrinol Metab,2004,89(9):4229-4233.
[16] Rivkees SA,Dinauer C.An optimal treatment for pediatric Graves’ disease is radioiodine.J Clin Endocrinol Metab,2007,92(3):797-800.
[17] Bahn Chair RS,Burch HB,Cooper DS,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clini-cal Endocrinologists.Thyroid,2011,21(6):593-646.
[18] 马寄晓.131I治疗甲状腺功能亢进症的远期观察.中华核医学杂志,1984,4(1):7-11.
[19] Chao M,Jiawei X,Guoming W,et al.Radioiodine treatment for pediatric hyperthyroid Grave’s disease.Eur J Pediatr,2009,168(10)1165-1169.
[20] 段东,罗加,李建国.青少年甲亢131I治疗后早发甲低的观察.重庆医学,2004,33(9):1387-1388.
[21] Zheng W,Jian T,Guizhi Z,et al.Analysis of 131I therapy and corre-lation factors of Graves,disease patients:a 4-year retrospective study.Nucl Med Commun,2012,33(1):97-101.
[22] 李佳,秦岚,任众,等.131I治疗青少年Graves病的量效分析.国际放射医学核医学杂志,2010,34(3):152-155.

相似文献/References:

[1]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[8]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
　Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[9]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[10]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[15]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[16]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[17]牟联超,李先映,石彩虹.131I治疗青少年Graves病58例临床分析[J].国际放射医学核医学杂志,2010,34(5):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
　MU Lian-chao,LI Xian-ying,SHI Cai-hong.Analyze of 131I therapy on 58 youngsters with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
[18]查金顺,黄春玲,蒋婷吟,等.131I治疗Graves甲状腺功能亢进症中碳酸锂的应用[J].国际放射医学核医学杂志,2011,35(2):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
　ZHA Jin-shun,HUANG Chun-ling,JIANG Ting-yin,et al.Application of lithium carbonate on radioiodine treatment of Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
[19]钟兴祥,郑吉祥,蓝冠章,等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
　ZHONG Xing-xiang,ZHENG Ji-xiang,LAN Guan-zhang,et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
[20]汤建林,李玉莹,高柳艳,等.131I治疗Graves病规范化建设体会[J].国际放射医学核医学杂志,2011,35(3):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
　TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.Standardization of 131I therapy for Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]

备注/Memo

备注/Memo:
收稿日期:2012-10-25。
基金项目:山西省回国留学人员科研资助项目(项目编号:2009101)
通讯作者:赵德善,Email:deshanzh@163.com
更新日期/Last Update: 1900-01-01